Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. S. Zimmermann, K. Jakob, W. von Wulffen, P. Huppmann, T. Meis, V. Arias Herrera, C. Baezner, F. Ihle, J. Geiseler, J. Fresenius, H. H. Leuchte, R. Baumgartner, J. Behr, C. Neurohr (Munich, Gauting, Bochum, Germany). Effect of PDE-5 inhibitor treatment in patients with interstitial lung disease and pulmonary hypertension. Eur Respir J 2011; 38: Suppl. 55, 3753

Member's Comments

No comment yet.

Related content which might interest you: Effect of phosphodiesterase 5 inhibitor in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003 Effect of simvastatin on pulmonary hypertension in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 287s Year: 2007 RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016 Determination of pulmonary hypertension degree in patients with interstitial lung diseases Source: Annual Congress 2010 - Different patterns of interstitial lung disease Year: 2010 A potential role for sildenafil in the management of pulmonary hypertension associated with parenchymal lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Comparison of acute hemodynamic effects of three different phosphodiesterase inhibitors in patients with pulmonary arterial hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004 Predictors of response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors Source: Eur Respir J, 50 (3) 1602425; 10.1183/13993003.02425-2016 Year: 2017 The effect of lung diseases on pulmonary hypertension and the effect of pulmonary hypertension on the lung Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Inhaled treprostinil therapy in patients with pulmonary hypertension and parenchymal lung disease Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Severe pulmonary hypertension in chronic lung disease. Long term effects on gas exchange of endothelin receptor antagonists or PDE5 inhibitors Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011 Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Pulmonary hypertension in patients with interstitial lung disease Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011 Treatment with sildenafil for pulmonary hypertension in pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Is sildenafil an effective bridging therapy to lung transplantation for patients with pulmonary hypertension in the setting of lung disease? Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Sildenafil is a potent pulmonary vasodilator in pulmonary hypertension associated with interstitial lung disease: impact on gas exchange properties Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Effect of baseline statin use on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019